Skip to main content

Advertisement

SpringerLink
Log in

Is there a need to redefine Parkinson’s disease?

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Parkinson’s disease (PD) is classically defined by its cardinal motor features and current clinical diagnostic criteria require the presence of bradykinesia and at least one additional motor symptom out of tremor, rigidity or postural instability. However, converging evidence from clinical, neuropathological, imaging and genetic research suggests initiation of PD-specific pathology prior to appearance of classical motor signs. This is of particular relevance in relation to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease. A key challenge in PD research, therefore, is to better characterize markers for the ‘preclinical’ stages of the illness. Development of PD criteria by combining such markers allowing for an early diagnosis and intervention could pave the way for the design and implementation of future disease modification trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Abbott RD, Petrovitch H, White LR et al (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57:456–462

    Article  PubMed  CAS  Google Scholar 

  • Abbott RD, Ross GW, White LR et al (2005) Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65:1442–1446

    Article  PubMed  CAS  Google Scholar 

  • Abbott RD, Ross GW, Petrovitch H et al (2007) Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 22:1581–1586

    Article  PubMed  Google Scholar 

  • Anheim M, Elbaz A, Lesage S et al (2012) Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 78:417–420

    Article  PubMed  CAS  Google Scholar 

  • Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649

    Article  PubMed  Google Scholar 

  • Beach TG, Adler CH, Dugger BN et al (2013) Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 72:130–136

    Article  PubMed  CAS  Google Scholar 

  • Behnke S, Schroeder U, Dillmann U et al (2009) Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 47:1237–1243

    Article  PubMed  CAS  Google Scholar 

  • Behnke S, Runkel A, Kassar HA et al (2012) Long-term course of substantia nigra hyperechogenicity in Parkinson’s disease. Mov Disord 28(4):455–459. doi:10.1002/mds.25193

    Article  PubMed  Google Scholar 

  • Bennett DA, Beckett LA, Murray AM (1996) Prevalence of Parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334:71–76

    Article  PubMed  CAS  Google Scholar 

  • Berg D, Poewe W (2012) Can we define “pre-motor” Parkinson’s disease? Mov Disord 27:595–596

    Article  PubMed  Google Scholar 

  • Berg D, Becker G, Zeiler B et al (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026–1031

    Article  PubMed  CAS  Google Scholar 

  • Berg D, Roggendorf W, Schroder U et al (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999–1005

    Article  PubMed  Google Scholar 

  • Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044–1055

    Article  PubMed  Google Scholar 

  • Berg D, Seppi K, Behnke S et al (2011) Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 68:932–937

    Article  PubMed  Google Scholar 

  • Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk populations for Parkinson’s disease: lessons from ongoing studies. Mov Disord 27:656–665

    Article  PubMed  Google Scholar 

  • Berg D, Lang AE, Postuma R et al (2013a) Changing the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities. Lancet Neurol 12(5):514–524

    Article  PubMed  Google Scholar 

  • Berg D, Behnke S, Seppi K et al (2013b) Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson’s disease. Mov Disord 28:216–219

    Article  PubMed  CAS  Google Scholar 

  • Berg D, Godau J, Seppi K et al (2013c) The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 20:102–108

    Article  PubMed  CAS  Google Scholar 

  • Besong-Agbo D, Wolf E, Jessen F et al (2013) Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80:169–175

    Article  PubMed  CAS  Google Scholar 

  • Bezard E, Gross CE, Brotchie JM (2003) Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated. Trends Neurosci 26:215–221

    Article  PubMed  CAS  Google Scholar 

  • Böttner M, Zorenkov D, Hellwig I et al (2012) Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis 48:474–480

    Article  PubMed  Google Scholar 

  • Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211

    Article  PubMed  Google Scholar 

  • Buchman AS, Shulman JM, Nag S et al (2012) Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 71:258–266

    Article  PubMed  Google Scholar 

  • Chen-Plotkin AS, Hu WT, Siderowf A et al (2010) Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 69:655–663

    Article  PubMed  Google Scholar 

  • Comella CL (2007) Sleep disorders in Parkinson’s disease: an overview. Mov Disord 22(S17):367–373

    Article  Google Scholar 

  • Del TK, Braak H (2012) Lewy pathology and neurodegeneration in premotor Parkinson’s disease. Mov Disord 27:597–607

    Article  Google Scholar 

  • Devic I, Hwang H, Edgar JS et al (2011) Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain 134:e178

    Article  PubMed  Google Scholar 

  • Dickson DW, Fujishiro H, DelleDonne A et al (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115:437–444

    Article  PubMed  Google Scholar 

  • Dickson DW, Braak H, Duda JE et al (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8:1150–1157

    Article  PubMed  CAS  Google Scholar 

  • Erro R, Picillo M, Vitale C et al (2013) Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84:14–17

    Article  PubMed  Google Scholar 

  • Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301

    Article  PubMed  Google Scholar 

  • Foulds PG, Mitchell JD, Parker A (2011) Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease. FASEB 25:4127–4137

    Article  CAS  Google Scholar 

  • Frauscher B, Nomura T, Duerr S et al (2012) Investigation of autonomic function in idiopathic REM sleep behavior disorder. J Neurol 259:1056–1061

    Article  PubMed  Google Scholar 

  • Fuente-Fernandez R, Schulzer M, Kuramoto L et al (2011) Age-specific progression of nigrostriatal dysfunction in Parkinson’s disease. Ann Neurol 69:803–810

    Article  PubMed  Google Scholar 

  • Gagnon JF, Postuma RB, Mazza S, Doyon J, Montplaisir J (2006) Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol 5:424–432

    Article  PubMed  Google Scholar 

  • Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752

    Article  PubMed  CAS  Google Scholar 

  • Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi K et al (2012) Neuroimaging: current role in detecting pre-motor Parkinson’s disease. Mov Disord 27:634–643

    Article  PubMed  Google Scholar 

  • Greffard S, Verny M, Bonnet AM et al (2006) Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 63:584–588

    Article  PubMed  Google Scholar 

  • Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22:839–842

    Article  PubMed  Google Scholar 

  • Haehner A, Boesveldt S, Berendse HW (2009) Prevalence of smell loss in Parkinson’s disease–a multicenter study. Parkinsonism Relat Disord 15:490–494

    Article  PubMed  CAS  Google Scholar 

  • Hilker R, Schweitzer K, Coburger S et al (2005) Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluoro dopa F 18 activity. Arch Neurol 62:378–382

    Article  PubMed  Google Scholar 

  • Hong Z, Shi M, Chung KA et al (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133:713–726

    Article  PubMed  Google Scholar 

  • International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG et al (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377:641–649

    Article  PubMed  Google Scholar 

  • Iranzo A, Molinuevo JL, Santamaria J et al (2006) Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5:572–577

    Article  PubMed  Google Scholar 

  • Iranzo A, Valldeoriola F, Lomena F et al (2011) Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 10:797–805

    Article  PubMed  CAS  Google Scholar 

  • Ishihara L, Brayne C (2006) A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol Scand 113:211–220

    Article  PubMed  CAS  Google Scholar 

  • Jankovic J, Poewe W (2012) Therapies in Parkinson’s disease. Curr Opin Neurol 25:433–447

    Article  PubMed  CAS  Google Scholar 

  • Kang JH, Caspell C, Coffey C et al (2012) Association between CSF biomarkers and clinical phenotype of early Parkinson’s disease in the Parkinson’s Progression Marker Initiative (PPMI). Mov Disord 27(S1):34–35

    Google Scholar 

  • Katzenschlager R, Lees AJ (2004) Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr Opin Neurol 17:417–423

    Article  PubMed  Google Scholar 

  • Khoo TK, Yarnall AJ, Duncan GW (2013) The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 80:276–281

    Article  PubMed  Google Scholar 

  • Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18:414–418

    Article  PubMed  Google Scholar 

  • Lesko LJ, Atkinson AJ Jr (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347–366

    Article  PubMed  CAS  Google Scholar 

  • Lill CM, Roehr JT, McQueen MB et al (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: the PDGene database. PLoS Genet 8:e1002548

    Article  PubMed  CAS  Google Scholar 

  • Louis ED, Bennett DA (2007) Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 22:1681–1688

    Article  PubMed  Google Scholar 

  • Maetzler W, Hausdorff JM (2012) Motor signs in the prodromal phase of Parkinson’s disease. Mov Disord 27:627–633

    Article  PubMed  Google Scholar 

  • Maetzler W, Mancini M, Liepelt-Scarfone I et al (2012) Impaired trunk stability in individuals at high risk for Parkinson’s disease. PLoS ONE 7:e32240

    Article  PubMed  CAS  Google Scholar 

  • Mahlknecht P, Stockner H, Nocker M et al (2012) A follow-up study of substantia nigra echogenicity in healthy adults. Mov Disord 27:1196–1197

    Article  PubMed  Google Scholar 

  • Marek K, Innis R, van DC et al (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 57:2089–2094

    Article  PubMed  CAS  Google Scholar 

  • McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269

    Article  PubMed  Google Scholar 

  • Miki Y, Tomiyama M, Ueno T, Haga R et al (2010) Clinical availability of skin biopsy in the diagnosis of Parkinson’s disease. Neurosci Lett 469:357–359

    Article  PubMed  CAS  Google Scholar 

  • Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM (2011) Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 69:193–197

    Article  PubMed  Google Scholar 

  • Mollenhauer B, Zhang J (2012) Biochemical premotor biomarkers for Parkinson’s disease. Mov Disord 27:644–650

    Article  PubMed  CAS  Google Scholar 

  • Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG (2011) Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with Parkinsonism: a cohort study. Lancet Neurol 10:230–240

    Article  PubMed  CAS  Google Scholar 

  • Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64:314–319

    Article  PubMed  CAS  Google Scholar 

  • Noyce AJ, Bestwick JP, Silveira-Moriyama L et al (2012) Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 72:893–901

    Article  PubMed  CAS  Google Scholar 

  • O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 23:101–106

    Article  PubMed  Google Scholar 

  • Parkinson Progression Marker Initiative (2011) The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95:629–635

    Article  Google Scholar 

  • Poewe W (2008) Non-motor symptoms in Parkinson’s disease. Eur J Neurol 15(S1):14–20

    Article  PubMed  Google Scholar 

  • Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173–181

    Article  PubMed  Google Scholar 

  • Ponsen MM, Stoffers D, Wolters ECh, Booij J, Berendse HW (2010) Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry 81:396–399

    Article  PubMed  Google Scholar 

  • Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J (2006) Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 66:845–851

    Article  PubMed  CAS  Google Scholar 

  • Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J (2009) Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72:1296–1300

    PubMed  CAS  Google Scholar 

  • Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir J (2011) Olfaction and color vision identify impending neurodegeneration in REM behavior disorder. Ann Neurol 69:811–818

    Article  PubMed  Google Scholar 

  • Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY (2012a) How does Parkinsonism start? Prodromal Parkinsonism motor changes in idiopathic REM sleep behavior disorder. Brain 135:1860–1870

    Article  PubMed  CAS  Google Scholar 

  • Postuma RB, Aarsland D, Barone P et al (2012b) Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 27:617–626

    Article  PubMed  Google Scholar 

  • Qiang JK, Wong YC, Siderowf A et al (2013) Plasma apolipoprotein A1 as a biomarker for Parkinson’s disease. Ann Neurol. doi: 10.1002/ana.23872. [Epub ahead of print]

  • Ray S, Britschgi M, Herbert C et al (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 13:1359–1362

    Article  PubMed  CAS  Google Scholar 

  • Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189

    Article  PubMed  Google Scholar 

  • Ross GW, Petrovitch H, Abbott RD et al (2004) Parkinsonian signs and substantia nigra neuron density in descendents elders without PD. Ann Neurol 56:532–539

    Article  PubMed  Google Scholar 

  • Ross GW, Abbott RD, Petrovitch H et al (2006) Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 21:2062–2067

    Article  PubMed  Google Scholar 

  • Ross GW, Petrovitch H, Abbott RD et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 63:167–173

    Article  PubMed  Google Scholar 

  • Savica R, Carlin JM, Grossardt BR et al (2009) Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73:1752–1758

    Article  PubMed  CAS  Google Scholar 

  • Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW (1986) Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 9:293–308

    PubMed  CAS  Google Scholar 

  • Scherfler C, Frauscher B, Schocke M et al (2011) White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 69:400–407

    Article  PubMed  Google Scholar 

  • Shannon KM, Keshavarzian A, Mutlu E et al (2012a) Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov Disord 27:709–715

    Article  PubMed  Google Scholar 

  • Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH (2012b) Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Mov Disord 27:716–719

    Article  PubMed  Google Scholar 

  • Shi M, Zabetian CP, Hancock AM et al (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett 480:78–82

    Article  PubMed  CAS  Google Scholar 

  • Shi M, Bradner J, Hancock AM et al (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69:570–580

    Article  PubMed  CAS  Google Scholar 

  • Shiba M, Bower JH, Maraganore DM et al (2000) Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 15:669–677

    Article  PubMed  CAS  Google Scholar 

  • Siderowf A, Lang AE (2012) Premotor Parkinson’s disease: concepts and definitions. Mov Disord 27:608–616

    Article  PubMed  CAS  Google Scholar 

  • Siderowf A, Jennings D, Eberly S et al (2012) Impaired olfaction and other prodromal features in the Parkinson at-risk syndrome study. Mov Disord 27:406–441

    Article  PubMed  Google Scholar 

  • Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361:1651–1661

    Article  PubMed  CAS  Google Scholar 

  • Stern MB, Lang A, Poewe W (2012) Toward a redefinition of Parkinson’s disease. Mov Disord 27:54–60

    Article  PubMed  Google Scholar 

  • Stiasny-Kolster K, Doerr Y, Möller JC et al (2005) Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126–137

    Article  PubMed  CAS  Google Scholar 

  • Tokuda T, Qureshi MM, Ardah MT et al (2010) Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:1766–1772

    Article  PubMed  CAS  Google Scholar 

  • Unger MM, Belke M, Menzler K et al (2010) Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 33:767–773

    PubMed  Google Scholar 

  • van Nuenen BF, Weiss MM, Bloem BR et al (2009) Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology 72:1041–1047

    Article  PubMed  Google Scholar 

  • Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ (1997) Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann Neurol 41:58–64

    Article  PubMed  CAS  Google Scholar 

  • Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R (2007) Parkinson’s disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 130:1799–1807

    Article  PubMed  Google Scholar 

  • Wang Y, Shi M, Chung KA et al (2012) Phosphorylated alpha-synuclein in Parkinson’s disease. Sci Transl Med 4:121

    Google Scholar 

  • Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA (2011) Alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson’s disease patients. PLoS ONE 6:e18513

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria

    Philipp Mahlknecht & Werner Poewe

Authors
  1. Philipp Mahlknecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Werner Poewe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Werner Poewe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahlknecht, P., Poewe, W. Is there a need to redefine Parkinson’s disease?. J Neural Transm 120 (Suppl 1), 9–17 (2013). https://doi.org/10.1007/s00702-013-1038-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-013-1038-5

Keywords

Search

Navigation